Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Eisai’s Q1 Operating Profit Drops 86% on Upfront Payment Receipt in FY2021
August 8, 2022
- 2024 Japan Filing Plan for Oncolytic Virus Unchanged: Oncolys President
August 8, 2022
- Sosei’s Schizophrenia Med Advancing into PII, Triggers US$30 Million from Neurocrine
August 8, 2022
- Eisai on Track towards Lecanemab PIII Readout by Sept.-End, Japan/US/EU Filing by March 2023
August 8, 2022
- Kyowa Kirin Books 12.3% Growth in H1 on Global Portfolios, 9.8 Billion Yen FX Gain
August 5, 2022
- Moderna Eyes mRNA Plant in Japan, but Multi-Year Purchase Pact a Must: Local President
August 5, 2022
- Shionogi Nabs Japan Commercial Rights to Grunenthal’s Osteoarthritis Drug
August 5, 2022
- Izcargo Fails to Win Approval in Brazil; JCR Aims for Refiling
August 4, 2022
- Trulicity Sales Alliance Deal to Expire by 2022-End: Lilly Japan/Sumitomo
August 4, 2022
- Mitsubishi to Review Biz Plan around Medicago’s COVID Jab, Reexamine Japan Timeline Too
August 4, 2022
- Mitsubishi Tanabe’s Q1 Sales Rise 2.9% on Growth in Japan
August 4, 2022
- Lenvima/Keytruda Combo Fails in PIII HCC Trial
August 4, 2022
- Japan Pharma Market to Reach 9.4 Trillion Yen in 2030: Fuji Keizai
August 4, 2022
- AstraZeneca, Tech Nation Link Arms to Help Startups Foray into Japan, UK
August 3, 2022
- Astellas Taps Ex-AstraZeneca Exec Taniguchi as New CMO
August 3, 2022
- Sawai Grabs Japan Rights to CureApp’s NASH Therapeutic App
August 3, 2022
- Sosei, AbbVie Expand Collaboration into Neurological Arena
August 3, 2022
- Ayumi to Boost Calonal Output to 2.88 Billion Tablets, Still August Shortage Likely
August 3, 2022
- Shionogi Eyes PIII Topline Readout for COVID Pill in Aug-Sept., Sticks to H1 Approval Plan
August 2, 2022
- Nipro to Temporarily Halt Some Cefazolin Supplies, Competitors Respond with Shipment Curbs
August 2, 2022
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…